3-methoxy-4-(phenoxymethyl)benzaldehyde | 1138154-21-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methoxy-4-(phenoxymethyl)benzaldehyde
• CAS: 1138154-21-8
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: PWUMRLLHXCQDLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.09
• 重原子数：
  18.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  35.53
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-methoxy-4-(phenoxymethyl)benzaldehyde 在 sodium tetrahydroborate 、 三溴化磷 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 4.58h， 生成 7-[3-aminomethyl-4-(4'-benzylxoy-3'-methxoybenzyloxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid dimesylate
  参考文献：
  名称：

  Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

  摘要：

  A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: <0.008-8 mu g/mL), although they are generally less active than the references against the Gram-negative strains. In particular, compound 111 (MIC: <0.008-4 mu g/mL) was found to be 8-2048 and 2-128 times more potent than levofloxacin (LVFX) and GMFX against the Gram-positive strains, respectively. Moreover, against MRSA clinical isolates, 111 (MIC90: 1 mu g/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 mu g/mL). Crown Copyright (C) 2012 Published by Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.010

文献信息

• Synthesis, thymidine phosphorylase, angiogenic inhibition and molecular docking study of isoquinoline derivatives
  作者：Khalid Zaman、Fazal Rahim、Muhammad Taha、Abdul Wadood、Syed Adnan Ali Shah、Mohammed Gollapalli、Farhat Ullah、Ashfaq Ahmed

  DOI：10.1016/j.bioorg.2019.102999

  日期：2019.8

  techniques such as 1H NMR, 13C NMR and EI-MS. The binding interactions of isoquinoline analogues with the active site of TP enzyme, the molecular docking studies were performed. Furthermore, the angiogenic inhibitory potentials of isoquinoline analogues (KA-1-9, 14, 12 and 16) were determined in the presence of standard drug Dexamethasone based on percentage inhibitions at various concentrations. Herein

  已经合成了异喹啉类似物（KA-1至16）并评估了它们对大肠杆菌胸苷磷酸化酶的抑制活性。除化合物11外，与标准药物7-地藏黄嘌呤相比（IC50 = 38.68±4.42 µM），所有其他类似物均显示出出色的胸苷抑制潜能，范围在4.40±0.20至69.30±1.80 µM之间。已针对所有化合物建立了结构活性关系，主要是基于苯环上的取代模式。所有类似物均通过各种光谱技术进行了表征，例如1H NMR，13C NMR和EI-MS。异喹啉类似物与TP酶活性位点的结合相互作用，进行了分子对接研究。此外，异喹啉类似物的血管生成抑制潜能（KA-1-9，14，根据不同浓度下的抑制百分数，在标准药物地塞米松的存在下确定12和16）。本文合成的类似物KA-12、14和16具有最强的血管生成抑制潜力。